GB0501638D0 - Particulates - Google Patents

Particulates

Info

Publication number
GB0501638D0
GB0501638D0 GBGB0501638.1A GB0501638A GB0501638D0 GB 0501638 D0 GB0501638 D0 GB 0501638D0 GB 0501638 A GB0501638 A GB 0501638A GB 0501638 D0 GB0501638 D0 GB 0501638D0
Authority
GB
United Kingdom
Prior art keywords
particulates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0501638.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to GBGB0501638.1A priority Critical patent/GB0501638D0/en
Priority to TW094103931A priority patent/TWI350762B/zh
Priority to ARP050100462A priority patent/AR047540A1/es
Priority to PE2009001024A priority patent/PE20091898A1/es
Priority to PE2005000160A priority patent/PE20050775A1/es
Priority to UY28744A priority patent/UY28744A1/es
Priority to JP2006552696A priority patent/JP5122823B2/ja
Priority to KR1020067018507A priority patent/KR101189038B1/ko
Priority to EP05708465A priority patent/EP1729731A1/en
Priority to US10/588,978 priority patent/US8920836B2/en
Priority to AU2005215239A priority patent/AU2005215239B2/en
Priority to NZ548962A priority patent/NZ548962A/en
Priority to CA2555423A priority patent/CA2555423C/en
Priority to BRPI0507683A priority patent/BRPI0507683A8/pt
Priority to PCT/GB2005/050014 priority patent/WO2005079760A1/en
Priority to EA200601468A priority patent/EA200601468A1/ru
Priority to CN2005800110496A priority patent/CN1942174B/zh
Publication of GB0501638D0 publication Critical patent/GB0501638D0/en
Priority to US11/574,778 priority patent/US20070259045A1/en
Priority to EP06703915A priority patent/EP1771160A2/en
Priority to BRPI0606339-0A priority patent/BRPI0606339A2/pt
Priority to CA002594373A priority patent/CA2594373A1/en
Priority to NZ590772A priority patent/NZ590772A/en
Priority to EP17154428.1A priority patent/EP3228308A1/en
Priority to CN2006800033121A priority patent/CN101132772B/zh
Priority to EA200701595A priority patent/EA015615B1/ru
Priority to KR1020097004935A priority patent/KR20090029856A/ko
Priority to JP2007552587A priority patent/JP5704789B2/ja
Priority to EP10180364A priority patent/EP2289491A1/en
Priority to AU2006208627A priority patent/AU2006208627B8/en
Priority to EP10180425A priority patent/EP2319499A1/en
Priority to NZ560669A priority patent/NZ560669A/xx
Priority to GEAP200610246A priority patent/GEP20105052B/en
Priority to MX2007009162A priority patent/MX2007009162A/es
Priority to PCT/EP2006/000727 priority patent/WO2006079550A2/en
Priority to AP2007004099A priority patent/AP2274A/xx
Priority to IL177313A priority patent/IL177313A/en
Priority to NO20064094A priority patent/NO20064094L/no
Priority to ZA200705913A priority patent/ZA200705913B/xx
Priority to IL184858A priority patent/IL184858A/en
Priority to TNP2007000293A priority patent/TNSN07293A1/fr
Priority to MA30117A priority patent/MA29368B1/fr
Priority to KR1020077019593A priority patent/KR100905511B1/ko
Priority to US13/157,093 priority patent/US20120141583A1/en
Priority to JP2012130265A priority patent/JP5746664B2/ja
Priority to JP2012284017A priority patent/JP2013100306A/ja
Priority to US14/547,874 priority patent/US20150148366A1/en
Priority to US15/367,095 priority patent/US20170079923A1/en
Priority to US15/886,659 priority patent/US20180153812A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/02—Making granules by dividing preformed material
    • B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B29K2033/04—Polymers of esters
    • B29K2033/12—Polymers of methacrylic acid esters, e.g. PMMA, i.e. polymethylmethacrylate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0085—Copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Mechanical Engineering (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
GBGB0501638.1A 2004-02-12 2005-01-28 Particulates Ceased GB0501638D0 (en)

Priority Applications (48)

Application Number Priority Date Filing Date Title
GBGB0501638.1A GB0501638D0 (en) 2005-01-28 2005-01-28 Particulates
TW094103931A TWI350762B (en) 2004-02-12 2005-02-05 Particulates
ARP050100462A AR047540A1 (es) 2004-02-12 2005-02-09 Particulados
PE2009001024A PE20091898A1 (es) 2004-02-12 2005-02-10 Particulados
PE2005000160A PE20050775A1 (es) 2004-02-12 2005-02-10 Formulaciones que comprenden multiparticulas de liberacion controlada
UY28744A UY28744A1 (es) 2004-02-12 2005-02-10 Particulados
JP2006552696A JP5122823B2 (ja) 2004-02-12 2005-02-11 微粒子
KR1020067018507A KR101189038B1 (ko) 2004-02-12 2005-02-11 미립자
EP05708465A EP1729731A1 (en) 2004-02-12 2005-02-11 Particulates
US10/588,978 US8920836B2 (en) 2004-02-12 2005-02-11 Particulates
AU2005215239A AU2005215239B2 (en) 2004-02-12 2005-02-11 Particulates
NZ548962A NZ548962A (en) 2004-02-12 2005-02-11 Melt Extruded Multiparticulates for the Controlled Release of an Active Ingredient
CA2555423A CA2555423C (en) 2004-02-12 2005-02-11 Melt-extruded multiparticulates for the controlled release of an active agent
BRPI0507683A BRPI0507683A8 (pt) 2004-02-12 2005-02-11 dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro
PCT/GB2005/050014 WO2005079760A1 (en) 2004-02-12 2005-02-11 Particulates
EA200601468A EA200601468A1 (ru) 2004-02-12 2005-02-11 Частицы
CN2005800110496A CN1942174B (zh) 2004-02-12 2005-02-11 微粒
US11/574,778 US20070259045A1 (en) 2005-01-28 2006-01-27 Alcohol Resistant Dosage Forms
EP06703915A EP1771160A2 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
BRPI0606339-0A BRPI0606339A2 (pt) 2005-01-28 2006-01-27 formas farmacêuticas resistentes a álcool
CA002594373A CA2594373A1 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
NZ590772A NZ590772A (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
EP17154428.1A EP3228308A1 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
CN2006800033121A CN101132772B (zh) 2005-01-28 2006-01-27 耐醇剂型
EA200701595A EA015615B1 (ru) 2005-01-28 2006-01-27 Устойчивые к спиртам лекарственные формы
KR1020097004935A KR20090029856A (ko) 2005-01-28 2006-01-27 알코올 저항성 제형
JP2007552587A JP5704789B2 (ja) 2005-01-28 2006-01-27 耐アルコール性剤形
EP10180364A EP2289491A1 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
AU2006208627A AU2006208627B8 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
EP10180425A EP2319499A1 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
NZ560669A NZ560669A (en) 2005-01-28 2006-01-27 Use of alkyl cellulose as controlled release matrix material in alcohol resistant dosage forms
GEAP200610246A GEP20105052B (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
MX2007009162A MX2007009162A (es) 2005-01-28 2006-01-27 Formas de dosis rsistente al alcohol.
PCT/EP2006/000727 WO2006079550A2 (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms
AP2007004099A AP2274A (en) 2005-01-28 2006-01-27 Alcohol resistant dosage forms.
IL177313A IL177313A (en) 2004-02-12 2006-08-06 Multi-part controlled release particles produced by extrusion by melting dry mixing including poly-unloaded polymer (ethyl acrylate, methyl acrylate) copolymer and opioid that provides resistance to abuse
NO20064094A NO20064094L (no) 2004-02-12 2006-09-12 Partikler
ZA200705913A ZA200705913B (en) 2005-01-28 2007-07-17 Alcohol resistant dosage forms
IL184858A IL184858A (en) 2005-01-28 2007-07-26 Alcohol resistant dosage forms
TNP2007000293A TNSN07293A1 (fr) 2005-01-28 2007-07-26 Formes posologiques resistant a l'extraction alcoolique
MA30117A MA29368B1 (fr) 2005-01-28 2007-07-27 Formes posologiques resistant a l'extraction alcoolique
KR1020077019593A KR100905511B1 (ko) 2005-01-28 2007-08-27 알코올 저항성 제형
US13/157,093 US20120141583A1 (en) 2004-02-12 2011-06-09 Alcohol resistant dosage forms
JP2012130265A JP5746664B2 (ja) 2004-02-12 2012-06-07 放出制御製剤処方物、単位用量形態、乾燥顆粒、マルチ粒子、調製方法、共重合体の使用、および製剤処方物における耐改ざん性を付与する方法
JP2012284017A JP2013100306A (ja) 2005-01-28 2012-12-27 耐アルコール性剤形
US14/547,874 US20150148366A1 (en) 2004-02-12 2014-11-19 Particulates
US15/367,095 US20170079923A1 (en) 2004-02-12 2016-12-01 Alcohol resistant dosage forms
US15/886,659 US20180153812A1 (en) 2004-02-12 2018-02-01 Alcohol resistant dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0501638.1A GB0501638D0 (en) 2005-01-28 2005-01-28 Particulates

Publications (1)

Publication Number Publication Date
GB0501638D0 true GB0501638D0 (en) 2005-03-02

Family

ID=34259727

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0501638.1A Ceased GB0501638D0 (en) 2004-02-12 2005-01-28 Particulates

Country Status (11)

Country Link
EP (3) EP2319499A1 (https=)
JP (2) JP5704789B2 (https=)
CN (1) CN101132772B (https=)
AP (1) AP2274A (https=)
EA (1) EA015615B1 (https=)
GB (1) GB0501638D0 (https=)
IL (1) IL184858A (https=)
MA (1) MA29368B1 (https=)
NZ (2) NZ590772A (https=)
TN (1) TNSN07293A1 (https=)
ZA (1) ZA200705913B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2010034342A1 (en) * 2008-09-24 2010-04-01 Evonik Röhm Gmbh Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
CA2755808C (en) * 2009-03-18 2016-01-19 Evonik Operations Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
EP2408437A1 (en) * 2009-03-18 2012-01-25 Evonik Röhm GmbH Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
PH12012502083A1 (en) * 2010-05-10 2017-07-26 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
US9700508B2 (en) * 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
EP2568965A1 (en) * 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
ES2628303T3 (es) * 2011-06-01 2017-08-02 Fmc Corporation Formas de dosis sólidas de liberación controlada
WO2013057570A2 (en) * 2011-10-18 2013-04-25 Purdue Pharma L.P. Acrylic polymer formulations
EP2838512B1 (en) * 2012-04-18 2018-08-22 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
RU2020117757A (ru) 2017-11-01 2021-11-29 Эджмонт Фармасьютикалс, Ллк Траст Оральные фармацевтические композиции лоразепама, устойчивые к спирту

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
PT1009387E (pt) * 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
DE19901085C2 (de) * 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
WO2003013476A1 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
CA2456322A1 (en) * 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
EP1492505B1 (en) * 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP1551402A4 (en) * 2002-09-23 2009-05-27 Verion Inc PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
ATE482695T1 (de) * 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US20060153915A1 (en) * 2003-01-23 2006-07-13 Amorepacific Corporation Sustained-release preparations and method for producing the same
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates

Also Published As

Publication number Publication date
JP2008528534A (ja) 2008-07-31
NZ590772A (en) 2012-05-25
EP2319499A1 (en) 2011-05-11
IL184858A0 (en) 2007-12-03
CN101132772A (zh) 2008-02-27
JP5704789B2 (ja) 2015-04-22
NZ560669A (en) 2012-09-28
MA29368B1 (fr) 2008-04-01
EP2289491A1 (en) 2011-03-02
TNSN07293A1 (fr) 2008-12-31
IL184858A (en) 2016-03-31
CN101132772B (zh) 2012-05-09
EP3228308A1 (en) 2017-10-11
ZA200705913B (en) 2008-08-27
AP2274A (en) 2011-08-19
EA200701595A1 (ru) 2008-02-28
AP2007004099A0 (en) 2007-08-31
JP2013100306A (ja) 2013-05-23
EA015615B1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
TWI350762B (en) Particulates
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006013270D1 (en) Prrs-impfstoffe
DE602006016093D1 (en) Cyanoanthranilamidinsektizide
GB0403100D0 (en) Particulates
GB0501638D0 (en) Particulates
DE602006003064D1 (en) Tripeptid- und tetrapeptid-thioether
GB0513284D0 (en) I-kinisis
DE602006009492D1 (en) Fluidmaschinen
GB0624980D0 (en) Modification
DE602006009835D1 (en) Nthalten
DE602006016951D1 (en) 2-cyanoacrylatzusammensetzung
DE602006014261D1 (en) Benzimidazolverbindungen
DE502005007477D1 (en) Delta-sigma-modulator
DE502006002219D1 (en) Rotationspumpe
DE602006015303D1 (en) Lecknachweisflicken
DE502006007734D1 (en) Thiazolcarbonsäureanilide
DE502006004337D1 (en) Strangführungsrolle
AU3401P (en) Archise Arctotis fastuosa
AU3621P (en) Scacover Scaevola aemula
AU4036P (en) Dottie Calathea roseo-picta
AU3685P (en) DOW10 Tristaniopsis laurina
AU3292P (en) DP303 Dianella prunina
AU3393P (en) Breakwell xTriticosecale
GB0525648D0 (en) Modification

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)